Latest Insider Transactions at Graybug Vision, Inc. (GRAY)
This section provides a real-time view of insider transactions for Graybug Vision, Inc. (GRAY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GRAYBUG VISION, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GRAYBUG VISION, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2022
|
Frederic Guerard |
SELL
Payment of exercise price or tax liability
|
Direct |
11,068
-6.56%
|
$0
$0.63 P/Share
|
|
Dec 01
2022
|
Frederic Guerard |
BUY
Exercise of conversion of derivative security
|
Direct |
28,125
+14.3%
|
-
|
|
Dec 01
2022
|
Parisa Zamiri Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,752
-4.56%
|
$0
$0.63 P/Share
|
|
Dec 01
2022
|
Parisa Zamiri Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+13.45%
|
-
|
|
Dec 01
2022
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,437
-3.94%
|
$0
$0.63 P/Share
|
|
Dec 01
2022
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,938
+10.23%
|
-
|
|
Nov 24
2022
|
Frederic Guerard |
SELL
Payment of exercise price or tax liability
|
Direct |
25,824
-15.53%
|
$0
$0.67 P/Share
|
|
Nov 24
2022
|
Frederic Guerard |
BUY
Exercise of conversion of derivative security
|
Direct |
65,625
+28.3%
|
-
|
|
Nov 24
2022
|
Parisa Zamiri Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,255
-13.94%
|
$0
$0.67 P/Share
|
|
Nov 24
2022
|
Parisa Zamiri Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,125
+32.2%
|
-
|
|
Nov 24
2022
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,726
-11.18%
|
$0
$0.67 P/Share
|
|
Nov 24
2022
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,125
+24.43%
|
-
|
|
Sep 23
2022
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,684
-2.78%
|
$0
$0.97 P/Share
|
|
Sep 04
2022
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+7.62%
|
-
|
|
Aug 19
2022
|
Parisa Zamiri Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,668
-7.9%
|
$0
$0.97 P/Share
|
|
Aug 19
2022
|
Parisa Zamiri Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+21.74%
|
-
|
|
Aug 19
2022
|
Frederic Guerard |
SELL
Payment of exercise price or tax liability
|
Direct |
6,596
-6.15%
|
$0
$0.97 P/Share
|
|
Aug 19
2022
|
Frederic Guerard |
BUY
Exercise of conversion of derivative security
|
Direct |
28,125
+20.77%
|
-
|
|
Aug 19
2022
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,347
-5.68%
|
$0
$0.97 P/Share
|
|
Aug 19
2022
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,937
+14.43%
|
-
|
|
Jun 09
2022
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.26%
|
-
|
|
May 19
2022
|
Frederic Guerard |
SELL
Payment of exercise price or tax liability
|
Direct |
33,357
-29.65%
|
$0
$0.9 P/Share
|
|
May 19
2022
|
Frederic Guerard |
BUY
Exercise of conversion of derivative security
|
Direct |
112,500
+50.0%
|
-
|
|
May 19
2022
|
Parisa Zamiri Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,123
-34.99%
|
$0
$0.9 P/Share
|
|
May 19
2022
|
Parisa Zamiri Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+50.0%
|
-
|
|
May 19
2022
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,290
-27.02%
|
$0
$0.9 P/Share
|
|
May 19
2022
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,750
+39.74%
|
-
|
|
Mar 31
2022
|
Robert S Breuil Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,188
-9.63%
|
$2,188
$1.25 P/Share
|
|
Mar 31
2022
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+18.04%
|
-
|
|
Dec 04
2021
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+22.01%
|
-
|
|
Sep 22
2021
|
Robert S Breuil Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,283
-36.42%
|
$21,849
$3.55 P/Share
|
|
Sep 22
2021
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
-
|
|
Sep 29
2020
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,562,500
+45.73%
|
$25,000,000
$16.0 P/Share
|
|
Sep 29
2020
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,719,213
+35.81%
|
-
|
|
Sep 29
2020
|
Clarus Lifesciences Iii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+11.47%
|
$4,000,000
$16.0 P/Share
|
|
Sep 29
2020
|
Clarus Lifesciences Iii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,680,395
+34.52%
|
-
|
|
Sep 29
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,600,847
+46.38%
|
-
|
|
Sep 25
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
562,500
+50.0%
|
$9,000,000
$16.0 P/Share
|